STL Volume 27 Number 2

3 POSTS 0 COMMENTS
Purchase PDF for $2.79Plerixafor on a WHIM – Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Emerging molecular experimental and clinical data suggests that CXCR4 may play an important role in other skin and systemic diseases including mycosis fungoides/Sézary syndrome, neurofibromatosis type 1 tumors, allergic reactions, Waldenström macroglobulinemia, melanoma, non-melanoma skin cancers and other solid tumors.
Transition of Topical Therapy Formulation in Psoriasis: Insights from a Canadian Practice Reflective
The benefits of transitioning from Cal/BD ointment or gel to aerosol foam formulation in this Canadian patient population were similar to those reported in clinical studies and were seen consistently among patients with a range of treatment priorities and with differing history of psoriasis severity and treatment history.
Update on Drugs & Devices: March-April 2022
This update covers Adalimumab biosimilar - Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar - Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet - Cibinqo® (Pfizer), Upadacitinib tablet - Rinvoq® (AbbVie), Risankizumab-rzaa SC injection - Skyrizi® (AbbVie), and HA-based dermal filler - Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).